Skip to main content

Table 2 Dosimetric parameters

From: Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

 

No. of pts.

Mean ± SD

Min

Max

Urethra D30 [Gy] at implantation (1)

167

185.5 ± 6.7

159.8

204.5

Prostate V [cc] at implantation (2)

150

31.9 ± 11.3

12.8

63.0

Prostate V [cc] postimplant (2)

163

31.8 ± 11.1

13.8

61.4

Prostate D90 [Gy] at implantation (3)

167

185.5 ± 4.0

173.7

198.4

Prostate D90 [Gy] postimplant (3)

165

179.2 ± 16.3

118.6

210.6

Prostate V100 [%] at implantation (4)

167

99.6 ± 0.5

97.5

100

Prostate V100 [%] postimplant (4)

165

94.9 ± 3.8

80.7

100

Prostate V90.6 [%] at implantation (5)

167

99.9 ± 0.2

98.4

100

Prostate V90.6 [%] postimplant (5)

165

97.0 ± 3.8

64.5

100

Rectum V100 [cc] at implantation (6)

167

0.3 ± 0.2

0

1.2

Rectum V100 [cc] postimplant (6)

165

0.5 ± 0.6

0

3.2

  1. (1) dose to 30% of the urethra.
  2. (2) volume of the prostate.
  3. (3) dose to 90% of the prostate.
  4. (4) percentage volume receiving 100% of the prescription dose.
  5. (5) percentage volume receiving 90.6% of the prescription dose.
  6. (6) volume of the rectum receiving 100% of the prescription dose.